The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
Revvity is positioning its technologies as a connected engine for discovery
The solution integrates key molecular cloning methods—including Golden Gate, Gibson assembly, and restriction/ligation—alongside primer design, Sanger sequencing analysis, and protein translation in a single application
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Facility designed to advance the next generation of imaging systems
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
Subscribe To Our Newsletter & Stay Updated
